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Renal cell carcinomaClear cell renal cell carcinoma (ccRCC) is a commonhumanmalignancy. Despite numerous efforts, there is still no
reliable biomarker or combination of biomarkers available for daily practice. Our study was designed to explore
the expression proﬁle of messenger RNA (mRNA) and long non-coding RNA (lncRNA) transcripts in ccRCC in
order to identify potential diagnostic biomarkers for patients with ccRCC. Total RNA from corresponding normal
andmalignant tissue of 15 patients with ccRCC was isolated. Expression proﬁling was performed using a custom
Agilent gene expression microarray which allowed the analysis of 34,144 mRNA and 32,183 lncRNA transcripts.
We observed that a subset of mRNA (n= 1064; 3.1%) and lncRNA (n= 1308; 4.1%) transcripts are dysregulated
(fold change N 2) in ccRCC tissue. The relative higher number of differentially expressed lncRNAs indicates that
lncRNA proﬁling may be better suited for diagnostic purposes; a number of so far unknown RNAs with potential
diagnostic interest in ccRCC are identiﬁed by our gene expression proﬁling study. The data are deposited in the
Gene Expression Omnibus (GSE61763).
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).al and clear cell renal
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2.1. Tissue samples
Tissue samples were prospectively collected from patients
undergoing partial or radical nephrectomy for renal tumors at the
Department of Urology at the University Hospital Bonn. Tumor
and normal renal tissue samples were fresh-frozen and stored at
−80 °C in the Biobank at the Centrum for Integrated Oncology at
the University Hospital Bonn. Histology of the tissue specimen
was conﬁrmed by a uropathologist using hematoxylin and eosin
staining. All patients provided written informed consent prior to
surgery. The study was approved by the local ethic committee
(280/12).
2.2. RNA preparation
The RNA isolation procedure was described in detail before [1]. In
brief, total RNA was isolated from approximately 50 mg frozen renal
tissue using the mirVana miRNA Isolation Kit (Ambion, Foster City, CA,
USA). Residual DNA fragments were removed by DNase-treatment
(Ambion DNA-free Kit). The RNA quality and quantity (A260/A280 ratio
close to 2, A260/A230 close to 2)was ﬁrst determinedwith theNanodrop
2000 spectrophotometer (Thermo Fisher Scientiﬁc, Waltham, MA, USA).
Additionally, agarose gel electrophoresis was performed to exclude RNAthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Bioanalyzer (Agilent Technologies, Santa Clara, CA) using the RNA
6000 Nano Kit; samples with a RNA Integrity Number (RIN) N6 were
used for expression proﬁling experiments.
2.3. Gene expression proﬁling
The RNA samples were shipped on dry ice to Biogazelle (Gent,
Belgium), where the gene expression microarray experiments were
performed as a contract service. A custom microarray based on the
Agilent SurePrint G3 technology was used to determine the expression
of 34,144 mRNA and 32,183 lncRNA transcripts. The lncRNA content is
based on LNCpedia 2.1 [2] and allowed proﬁling of 17,5125 lncRNA
genes.
The workﬂow at Biogazelle was as follows: 100 ng total RNAwas la-
beled using the low input Quick Amp labeling Kit (Agilent Technolo-
gies). The labeled RNA was then hybridized to the custom gene
expression microarray (AMADID #041648). The microarrays were
scanned using an Agilent G2565CA Microarray Scanner with the Scan
Control software v8.5. The Probe intensities were extracted using the
Agilent Feature Extraction software, and probe intensities were back-
ground corrected and normalized (quantile normalization) using the
LIMMA package in R. All procedures were performed according to the
manufacturer's instructions.
The background subtracted and normalized expression data were
groupwise normalized deducting group mean values. Pairwise fold
change, for each gene, was calculated by dividing ccRCC group mean
of RNA expression by normal groupmean RNA expression levels. Corre-
lation analysis was performed using the R-Base Package v3.0.2 applyingFig. 1. The heatmap is showing the 100 most differentially expressed mRNA (A) and lncRNA (
range from green (up-regulation) to red (down-regulation). The columns represent individual t
cluster. The rows represent individual genes.the Pearson's correlation coefﬁcient. In order to identify clinically rele-
vant dysregulated RNA transcripts, we considered differential expres-
sion as present if the fold-change was N2, and the adjusted p-value
(false discovery rate) was p b 0.05. A heatmap (see Fig. 1) was created
using ArrayMining [3].3. Discussion
So far, there is no biomarker for ccRCC available for daily practice [4].
Our gene expression proﬁle of 15 corresponding normal and malignant
renal tissue samples from patients with ccRCC indicated dysregulation
of 3.1% (368 upregulated and 696 downregulated transcripts) of
mRNA and 4.1% (568 upregulated and 740 downregulated transcripts)
of lncRNA transcripts in ccRCC tissue. As expected, the mRNA and
lncRNA expression proﬁles allowed distinguishing normal and malig-
nant tissue samples accurately based on the molecular signature. Inter-
estingly, the expression changes seemed to bemore pronouncedwithin
the subgroup of lncRNA than mRNA molecules, suggesting that lncRNA
could be better suited as diagnostic biomarker. An earlier comparison of
SAGE libraries of a broad spectrum of normal and tumor tissues also
indicated a highly aberrant lncRNA expression proﬁle in human can-
cers, as well as a tissue speciﬁc lncRNA expression proﬁle [5]. Other
researchers also reported lncRNA expression proﬁles in ccRCC tissue
[6,7], but the analyses were restricted to small cohorts thereby limit-
ing powerful statistics. Nevertheless, it is obvious that unique
lncRNA expression proﬁles exist in ccRCC, and the identiﬁcation of
novel differentially expressed lncRNA is an important step towards
better understanding of ccRCC.B) transcripts in ccRCC and normal renal tissue. Expression levels are coded in colors and
issue samples; all ccRCC (blue) and normal (yellow) samples are locatedwithin a separate
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We have identiﬁed an expression proﬁle of mRNA and lncRNA in
ccRCC and normal renal tissue, and RNA expression levels allowed accu-
rate identiﬁcation of tumor tissue based on themolecular signature. Our
study provides novel insights and thus a better understanding of ccRCC
carcinogenesis.
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